title: Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina.
authors.forename: L M
authors.initials: LM
authors.lastname: Biasucci
authors.forename: M
authors.initials: M
authors.lastname: Lombardi
authors.forename: M
authors.initials: M
authors.lastname: Piro
authors.forename: G
authors.initials: G
authors.lastname: Di Giannuario
authors.forename: G
authors.initials: G
authors.lastname: Liuzzo
authors.forename: F
authors.initials: F
authors.lastname: Crea
mesh_terms: D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D013777:Tetrazoles; D002097:C-Reactive Protein; D000077405:Irbesartan